Live
- Three persons admitted to hospital for diarrhea treatment
- First Star Outside Milky Way Captured: WOH G64 is 2,000 Times Larger Than the Sun
- Sikkim govt to constitute state Niti Ayog: CM Tamang
- CBI books Rajasthan narcotics inspector for Rs 3 lakh bribe
- Rajasthan bypolls: A tough contest between BJP and Congress
- Albania joins SEPA, paving way for EU integration
- Japanese government approves 250-billion USD economic package to ease price pain
- Six pharma companies to set up their units in Telangana
- The Unstable Events of a 17-Wicket Day in Perth: India vs Australia
- Dutch FM's Israel trip cancelled after Netanyahu's arrest warrant
Lupin launches Doxercalciferol drug in US
Drug firm Lupin on Thursday said it has launched its generic Doxercalciferol injection used for treatment of hyperparathyroidism in the US market.
New Delhi: Drug firm Lupin on Thursday said it has launched its generic Doxercalciferol injection used for treatment of hyperparathyroidism in the US market.
The company has launched Doxercalciferol injection, 4 mcg/2 mL (2 mcg/mL) multi-dose vials, after having received an approval from the United States Food and Drug Administration (USFDA) earlier, Lupin said in a statement.
The product is a generic version of Sanofi Genzyme's Hectorol injection, 4 mcg/2 mL (2 mcg/mL) multi-dose vials, it added.
According to the IQVIA MAT October 2019 data, Doxercalciferol injection, 4 mcg/2 mL (2 mcg/mL) multi-dose vials had an annual sales of around $132 million in the US, Lupin said.
"It is indicated for the treatment of secondary hyperparathyroidism in adult patients with chronic kidney disease on dialysis," it added.
